Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Sponsor: FLX Bio, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS7290
U.S. Govt. ID: NCT03674567
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is designed to test different doses of FLX475 to see if it is safe and to study how the drug is absorbed and how the human body gets rid of the drug. The study will test FLX475 alone and in combination with pembrolizumab, a drug already approved by the United States Food and Drug Administration (FDA) for the treatment of patients with certain types of cancers. Pembrolizumab also works to stimulate your immune system and is also known as a checkpoint inhibitor. The objective of the study is to assess the safety and activity of FLX475 alone and FLX475 in combination with pembrolizumab at different dosages in patients with different cancers.
This study is closed
Investigator
Jennifer Amengual, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with a metastatic tumor that has progressed after treatment with other therapies? Yes No
Are you able to swallow tablets without difficulty? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162